With new information, Exelixis takes one other shot at prostate most cancers therapy

In 2014, the Bay Space biotech firm Exelixis (EXEL) tried to develop a drug for prostate most cancers; its medical trial led to failure and almost shut down the corporate. A second try has delivered higher, tumor-shrinking outcomes, in response to information launched Monday, whereas nonetheless leaving some vital questions unanswered.

In an interim take a look at the continued research, a mix routine consisting of Exelixis’ focused most cancers drug Cabometyx and Roche’s checkpoint inhibitor Tecentriq demonstrated a tumor response fee of 32%. The median length of response was 8.three months.

Unlock this text by subscribing to STAT Plus. To get you began, take pleasure in 50% off your first three months!


What’s it?

STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, coverage, and life science protection and evaluation.
Our award-winning crew covers information on Wall Avenue, coverage developments in Washington, early science breakthroughs and medical trial outcomes, and well being care disruption in Silicon Valley and past.

What’s included?

  • Each day reporting and evaluation
  • Probably the most complete trade protection from a powerhouse crew of reporters
  • Subscriber-only newsletters
  • Each day newsletters to transient you on a very powerful trade information of the day
  • On-line intelligence briefings
  • Frequent alternatives to interact with veteran beat reporters and trade specialists
  • Unique trade occasions
  • Premium entry to subscriber-only networking occasions across the nation
  • The perfect reporters within the trade
  • Probably the most trusted and well-connected newsroom within the well being care trade
  • And far more
  • Unique interviews with trade leaders, profiles, and premium instruments, like our CRISPR Trackr.

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker